Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 2, 2010, Pages 125-131

  Lappin, Graham ^a   Shishikura, Yoko ^a   Jochemsen, Roeline ^b   Weaver, Richard John ^b   Gesson, Charlotte ^b   Houston, Brian ^c   Oosterhuis, Berend ^d   Bjerrum, Ole J ^e   Rowland, Malcolm ^c   Garner, Colin ^a  

^a Xceleron Ltd   (United Kingdom)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d PRA Health Sciences   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Absolute oral bioavailability; Accelerator mass spectrometry; AMS fexofenadine; Microdosing

Indexed keywords

CARBON 14; FEXOFENADINE;

ACCELERATOR MASS SPECTROMETRY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MICRODOSIMETRY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; RADIOACTIVITY; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; TERFENADINE; YOUNG ADULT;

EID: 77952239982     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.009     Document Type: Article

References (29)

1. Beaumont K., Smith D.A. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?. Curr. Opin. Drug Discov. Dev. 2009, 12(1):61-71.
2. Bertino J.S., Greenberg H.E., Reed M.D. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 2007, 47(4):418-422.
3. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R. Dev. 2007, 8(5):301-314.
4. Cvetkovic M., Leake B., Fromm M.F., Wilkinson G.R., Kim R.B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 1999, 27(8):866-871.
5. Davis S.S., Hardy J.G., Fara J.W. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986, 27(8):886-892.
6. Golightly L.K., Greos L.S. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005, 65(3):341-384.
7. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., Hall S.D. The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 2001, 69(3):114-121.
8. ICH Topic M3 note for guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95, December, 2009.
9. Lappin G., Garner C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 2008, 4(12):1499-1506.
10. Lappin G., Garner R.C. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2003, 2(3):233-240.
11. Lappin G., Kuhnz W., Jochemsen R., Kneer J., Chaudhary A., Oosterhuis B., Drijfhout W.J., Rowland M., Garner R.C. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin. Pharmacol. Ther. 2006, 80(3):203-215.
12. Lappin G., Rowland M., Garner R.C. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin. Drug Metab. Toxicol. 2006, 2(3):419-427.
13. Lappin G., Simpson M., Shishikura Y., Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal. Biochem. 2008, 378:93-95.
14. Lippert C., Ling J., Brown P., Burnmaster S. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm. Res. (N.Y.) 1996, 12:S-390.
15. Madan A., O'Brien Z., Wen J., O'Brien C., Farber R.H., Beaton G., Crowe P., Oosterhuis B., Garner R.C., Lappin G., Bozigian H.P. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br. J. Clin. Pharmacol. 2008, 67(3):288-298.
16. Matsushima S., Maeda K., Hayashi H., Debori Y., Schinkel A.H., Schuetz J.D., Kusuhara H., Sugiyama Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 2008, 73(5):1474-1483.
17. Ogasawara A., Kume T., Kazama E. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab. Dispos. 2007, 35(3):410-418.
18. Peng S.X., Ritchie D.M., Cousineau M., Danser E., Dewire R., Floden J. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J. Pharm. Sci. 2006, 95(9):1984-1993.
19. Petri N., Tannergren C., Rungstad D., Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 2004, 21(8):1398-1404.
20. Robbins D.K., Castles M.A., Pack D.J., Bhargava V.O., Weir S.J. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm. Drug Dispos. 1998, 19(7):455-463.
21. Rowland M. Commentary on ACCP position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 2007, 47(12):1595-1596. (author reply 1597-8).
22. Shimizu M., Fuse K., Okudaira K., Nishigaki R., Maeda K., Kusuhara H., Sugiyama Y. Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 2005, 33(10):1477-1481.
23. Tahara H., Kusuhara H., Endou H., Koepsell H., Imaoka T., Fuse E., Sugiyama Y. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J. Pharmacol. Exp. Ther. 2005, 315(1):337-345.
24. Tahara H., Kusuhara H., Fuse E., Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos. 2005, 33(7):963-968.
25. Tillement J.P. The advantages for an H1 antihistamine of a low volume of distribution. Allergy 2000, 55(Suppl. 60):17-21.
26. Uno T., Shimizu M., Sugawara K., Tateishi T. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab. Dispos. 2006, 34(11):1875-1879.
27. Williams M.F., Dukes G.E., Heizer W., Han Y.H., Hermann D.J., Lampkin T., Hak L.J. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm. Res. 1992, 9(9):1190-1194.
28. Yamane N., Tozuka Z., Sugiyama Y., Tanimoto T., Yamazaki A., Kumagai Y. Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 858(1-2):118-128.
29. Zhao R., Kalvass J.C., Yanni S.B., Bridges A.S., Pollack G.M. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metab. Dispos. 2009, 37(3):529-535.